CV Sciences Inc (CVSI)

[Gladys Thong]

More relevant to NRT-drug candidates like CVSI-007:

DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-IN-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE AND ABSTINENCE



Note the 10X "Total Funding".

Click on DESCRIPTION

Relapse to smoking is very common after initial abstinence with pharmacotherapy and represents a major clinical challenge. 24-week abstinence rates for all three available pharmacotherapies is still poor and averages only 22% for varenicline, 16% for bupropion, and 16% for nicotine replacement therapies, compared to 9% for placebo.
. . .
These new medication candidates show superior efficacy in inhibiting nicotine taking and relapse in animal models, and may have a better outcome than existing treatments for maintenance of abstinence and prevention of relapse. Such new approaches are urgently needed, since the current repertoire of smoking cessation medications are not approved for longer term treatment due to safety concerns and have less than 45% quit success and even poorer abstinence (high rates of relapse) post 6 months.